Federico de la Rosa-Kehrmann

Hospital Universitario 12 De Octubre

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Felipe Villacampa

Clinica Universidad de Navarra

F. Guerrero-Ramos

Hospital Universitario 12 De Octubre

A. Rodrı́guez-Antolı́n

Hospital Universitario 12 De Octubre

J.M. Duarte-Ojeda

Hospital Universitario 12 De Octubre

J.B. Passas-Martínez

Hospital Universitario 12 De Octubre

José Medina‐Polo

Hospital Universitario 12 De Octubre

ÁT

Á. Tejido Sánchez

Hospital Universitario 12 De Octubre

M. Pamplona-Casamayor

Research Institute Hospital 12 de Octubre

Amado Andrés-Belmonte

Research Institute Hospital 12 de Octubre

J.M. Cózar

Hospital Universitario Virgen de las Nieves

Cooperative Institutions

Hospital Universitario 12 De Octubre

Research Institute Hospital 12 de Octubre

Universidad Complutense de Madrid

Puigvert Foundation

Asociación Española de Urología

Centro de Investigación Biomédica en Red de Cáncer

Universitat Autònoma de Barcelona

Hospital Universitario HM Madrid

Universitat de Barcelona

Hospital Universitario Puerta de Hierro Majadahonda

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Testicular tumors: residual retroperitoneal mass surgery after chemotherapy;Is it possible to predict their histology?

PubMed (2011)

José Medina‐Polo V.M. Martínez-Silva M. Domínguez-Esteban Federico de la Rosa-Kehrmann Felipe Villacampa

We present our series of residual retroperitoneal mass surgery after chemotherapy. We evaluate possible preoperative parameters that can predict the retroperitoneal mass histology. Survival and relapse rates were also evaluated.We reviewed sixty resections of residual retroperitoneal masses of testicular tumours after chemotherapy performed at our department between 1995 and 2007. We evaluate the relationship between histology of the retroperitoneal mass and possible risk factors, such as outcomes after chemotherapy, which was evaluated as changes in the size of the retroperitoneal mass, and negativization of serum tumor markers. We also evaluate histology and size of the primary testicular cancer.The histology of retroperitoneal mass was necrosis or fibrosis in 25 (42%) cases, teratoma in 29 (48%) and viable tumor in 6 (10%). The size of the retroperitoneal mass decreased after the chemotherapy in 62% cases; moreover negative serum tumor markers were found in 87%. Elevated values of human chorionic gonadotropin were associated with viable cells in the retroperitoneal mass (p=0.014) and, the presence of teratoma in the primary tumor may be associated with teratoma in the retroperitoneal mass histology (p=0.002). However, no other preoperative factors that predict the residual mass histology were found. Repeated resections of retroperitoneal masses were required in four patients and 9 patients died during follow-up.We cannot determine preoperative parameters that accurately predict the histology of retroperitoneal masses. Therefore, resection of residual retroperitoneal masses after chemotherapy in non-seminomatous germ cell tumours must be performed.

Histology

Immature teratoma

Retroperitoneal space

Source

Cite

Citations (1)

Kidney transplantation with grafts from old donors: Is there a difference in term of complications and survival outcomes?

European Urology Supplements (2017)

José Medina‐Polo Raquel Sopeña Sutil R. Benítez-Sala Federico de la Rosa-Kehrmann M. Pamplona-Casamayor

10.1016/s1569-9056(17)31191-0

Cite

Citations (0)

Incidental diagnosis of bladder cancer in a national observational study in spain

Actas Urológicas Españolas (English Edition) (2022)

Josep María Gaya A. Territo Solomon L. Woldu I. Schwartzmann Paolo Verri

Presentation (obstetrics)

Demographics

10.1016/j.acuroe.2022.09.005

Cite

Citations (2)

Diagnóstico incidental del cáncer de vejiga en España. Estudio observacional a nivel nacional

Actas Urológicas Españolas (2022)

Josep María Gaya A. Territo Solomon L. Woldu I. Schwartzmann Paolo Verri

10.1016/j.acuro.2022.09.002

Cite

Citations (1)

Adjuvant intravesical treatment for non-muscle invasive bladder cancer: The importance of the strain and maintenance

Actas Urológicas Españolas (English Edition) (2017)

F. Guerrero-Ramos A. Lara-Isla J. Justo-Quintas J.M. Duarte-Ojeda Federico de la Rosa-Kehrmann

Maintenance therapy

Strain (injury)

10.1016/j.acuroe.2017.08.008

Cite

Citations (5)

La survie des transplantations rénales des donneurs à cœur non battant incontrôlés sous la protection normothermique : sont-ils aussi bons que les reins des donneurs à cœur battant ?

Progrès en Urologie (2017)

F. Guerrero-Ramos T. Cavero-Escribano Federico de la Rosa-Kehrmann A. Rodrı́guez-Antolı́n M. Pamplona-Casamayor

10.1016/j.purol.2017.07.081

Cite

Citations (0)

MP43-08 BCG VS CHEMOHYPERTHERMIA WITH MITOMYCIN C FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CARCINOMA: PRELIMINARY RESULTS OF HIVEC-HR RANDOMIZED CLINICAL TRIAL

The Journal of Urology (2019)

F. Guerrero-Ramos Daniel A. González‐Padilla Alejandro González-Díaz J.M. Duarte-Ojeda N. Miranda-Utrera

You have accessJournal of UrologyBladder Cancer: Non-invasive III (MP43)1 Apr 2019MP43-08 BCG VS CHEMOHYPERTHERMIA WITH MITOMYCIN C FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CARCINOMA: PRELIMINARY RESULTS OF HIVEC-HR RANDOMIZED CLINICAL TRIAL Félix Guerrero-Ramos*, Daniel Antonio González-Padilla, Alejandro González-Díaz, José Manuel Duarte-Ojeda, Natalia Miranda-Utrera, Felipe Villacampa-Aubá, and Federico de la Rosa-Kehrmann Félix Guerrero-Ramos*Félix Guerrero-Ramos* More articles by this author , Daniel Antonio González-PadillaDaniel Antonio González-Padilla More articles by this author , Alejandro González-DíazAlejandro González-Díaz More articles by this author , José Manuel Duarte-OjedaJosé Manuel Duarte-Ojeda More articles by this author , Natalia Miranda-UtreraNatalia Miranda-Utrera More articles by this author , Felipe Villacampa-AubáFelipe Villacampa-Aubá More articles by this author , and Federico de la Rosa-KehrmannFederico de la Rosa-Kehrmann More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000556231.44325.78AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVES: After the BCG shortage happened several years ago, there is an increasing interest in finding a valid alternative for patients with non-muscle invasive bladder cancer (NMIBC). HIVEC-HR is a pilot study that aims to compare efficacy and safety between BCG and chemohyperthermia (CHT) with mitomycin C (MMC). Here we present our preliminary results once randomization has been completed. METHODS: Open pilot randomized clinical trial 1:1 including patients with high-risk NMIBC according to EAU Guidelines (EudraCT 2016-001186-85). Patients with CIS, intolerance or contraindication for receiving BCG or MMC were excluded. Patients were randomly assigned to one of the following groups: - BCG (TICE strain): 50 mg diluted in 50 mL of sterile saline held for 2 hours in the bladder, one weekly instillation for 6 weeks and maintenance according to SWOG protocol. - CHT: 40 mg MMC diluted in 40 mL of distilled water at 43°C using COMBAT® recirculation system for 60 minutes, one weekly instillation for 6 weeks and one monthly instillation for 6 months. Follow-up was carried out with cytology and cystoscopy every 3 months as well as upper urinary tract imaging yearly, as stated by EAU Guidelines. Primary endpoint was recurrence-free survival at 24 months. Secondary objectives were to evaluate safety, progression rate, overall survival and quality of life. RESULTS: Fifty patients have been randomized (100% recruitment completed), with 48 finally starting treatment. Median age is 73 years old, 87.6% were males and 83% were primary tumours. Baseline characteristics were comparable in both groups. Median follow-up is 12.3 months from TURBT. For the BCG group, 5 recurrences and 4 progressions to T2 were reported, and only 1 progression happened in the CHT group with no recurrences (see figure). Regarding safety profile, adverse events (AE) appeared in 11 patients in the CHT group and 9 in the BCG group. In relation to the severity of these AEs, 4 patients in each group presented CTCAE grade 3 complications, although 3/4 in the CHT group were treatment withdrawals due to MMC allergy. More patients in the BCG group had to discontinue due to AE (6 vs 4). Four patients have died so far, none of them related with their bladder cancer. CONCLUSIONS: According to our trial preliminary results, CHT in high risk NMIBC patients seems not to be inferior to BCG in terms of efficacy. Moreover, patients under CHT have a higher therapeutic adherence than those under BCG treatment. Source of Funding: None. Madrid, Spain© 2019 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 201Issue Supplement 4April 2019Page: e620-e620 Advertisement Copyright & Permissions© 2019 by American Urological Association Education and Research, Inc.MetricsAuthor Information Félix Guerrero-Ramos* More articles by this author Daniel Antonio González-Padilla More articles by this author Alejandro González-Díaz More articles by this author José Manuel Duarte-Ojeda More articles by this author Natalia Miranda-Utrera More articles by this author Felipe Villacampa-Aubá More articles by this author Federico de la Rosa-Kehrmann More articles by this author Expand All Advertisement PDF downloadLoading ...

10.1097/01.ju.0000556231.44325.78

Cite

Citations (2)

72 Kidney transplantation from donors after circulatory determination of death: Evaluation prognostic factors for delayed graft function and graft survival

European Urology Supplements (2016)

José Medina‐Polo L. García-González J. Justo-Quintas J. Gil-Moradillo F. Guerrero-Ramos

10.1016/s1569-9056(16)60074-x

Cite

Citations (0)

Survival Analysis of Kidney Transplants with Grafts from Uncontrolled DCD Donors under Normothermic Preservation Prior to Organ Retrieval Related to DBD

Transplantation (2018)

F. Guerrero-Ramos Teresa Cavero A. Rodrı́guez-Antolı́n Federico de la Rosa-Kehrmann M. Pamplona-Casamayor

Introduction and Objectives Kidney transplantation is the best treatment for end-stage chronic kidney disease, with multiple advantages over dialysis. Because of the large quantity of people awaiting a kidney transplant there is an important organ shortage, which has led to investigate new sources of grafts. Donation after cardiac death (DCD) has emerged in the last two decades to increase the donor pool, classically composed by donation after brain death (DBD). Uncontrolled DCD is popular in not many countries, because of ethical issues among others; moreover, these kidneys have a higher ischemic risk due to longer cold ischemia time. In this series, we compare the survival of uncontrolled DCD transplants related to DBD transplants. Methods We carried out a retrospective review of 300 kidney transplants (150 uncontrolled DCD with normothermic perfusion and 150 DBD) performed in our centre between 2007 and 2012 on recipients under 60 years old. We collected preoperative features, surgical technique, graft characteristics (cold ischemia time) and postoperative events. We estimated crude survival and death-censored and primary non function-censored survival with Kaplan Meier curves, using Stata v12.0 for Windows. Results Both groups were comparable regarding baseline characteristics, with a median follow-up of 53.6 months (interquartile range 35.3-70.5), and a median age of 43 years for donors and 46 for recipients. Crude survival (Figure 1) at 1, 5 and 10 years was 93.3%, 90.9% and 88.5% for DBD kidneys and 91.1%, 83.6% and 81.6% for uncontrolled DCD grafts, with no statistically significant difference (p=0,100). Primary non function and death censored survival (Figure 2) at 1, 5 and 10 years was 95.6%, 93% and 88.7% for DBD grafts and 97%, 88.9% and 86.9% for DCD grafts..Conclusions Uncontrolled DCD kidneys under normothermic preservation have similar survival as DBD grafts. Hence, they can be considered as a valuable source to increase the donor pool so as to minimize the current organ shortage.

Interquartile range

Machine Perfusion

Economic shortage

Allotransplantation

10.1097/01.tp.0000543181.86070.6d

Cite

Citations (1)

MP01-16 IL-10 AND CXCL10 URINE QUANTIFICATION AS USEFUL BIOMARKERS TO PREDICT BCG RESPONSE IN BLADDER CANCER PATIENTS

The Journal of Urology (2020)

F. Guerrero-Ramos P. Abad-López Cristian Suárez-Cabrera Marta Rodríguez-Izquierdo Carmen Gómez del Cañizo

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I (MP01)1 Apr 2020MP01-16 IL-10 AND CXCL10 URINE QUANTIFICATION AS USEFUL BIOMARKERS TO PREDICT BCG RESPONSE IN BLADDER CANCER PATIENTS Felix Guerrero-Ramos*, Pablo Abad-Lopez, Cristian Suarez-Cabrera, Marta Rodriguez-Izquierdo, Carmen Gomez-Cañizo, Federico de la Rosa-Kehrmann, Victor Garcia-Martinez, Alejandra Bernardini, Iris Lodewijk, Guillermo Paramio, Alfredo Rodriguez-Antolin, Jesus M Paramio, and Marta Dueñas Felix Guerrero-Ramos*Felix Guerrero-Ramos* More articles by this author , Pablo Abad-LopezPablo Abad-Lopez More articles by this author , Cristian Suarez-CabreraCristian Suarez-Cabrera More articles by this author , Marta Rodriguez-IzquierdoMarta Rodriguez-Izquierdo More articles by this author , Carmen Gomez-CañizoCarmen Gomez-Cañizo More articles by this author , Federico de la Rosa-KehrmannFederico de la Rosa-Kehrmann More articles by this author , Victor Garcia-MartinezVictor Garcia-Martinez More articles by this author , Alejandra BernardiniAlejandra Bernardini More articles by this author , Iris LodewijkIris Lodewijk More articles by this author , Guillermo ParamioGuillermo Paramio More articles by this author , Alfredo Rodriguez-AntolinAlfredo Rodriguez-Antolin More articles by this author , Jesus M ParamioJesus M Paramio More articles by this author , and Marta DueñasMarta Dueñas More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000815.016AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Identifying biomarkers to predict BCG response before beginning the treatment is an unsolved need in the clinical practice for patients with high risk non-muscle invasive bladder cancer. Nowadays, there is no method to predict BCG response in our patients. In this context, protumor activity of M2 macrophages could be mediating this treatment response, so evaluation of cytokines as IL-10 and CXCL10 in urine could be an indicator of their activity on patient’s urothelium. The main aim of this work is to evaluate if expression levels of IL-10 and CXCL10 in urine samples obtained before treatment are able to identify BGC responders and non-responders. We also aimed to find out the correlation of these levels in urine with the presence of M2 macrophages in tumor tissue samples obtained after transurethral resection of the bladder tumor (TURBT) and before the onset of BCG instillations. METHODS: Tumor tissue samples as well as urine samples were collected from a paired sample set (n= 20) from patients before BCG treatment at our Urology Department. Response to BCG instillations was defined as no recurrence after 2 years. Informed consent was obtained from all patients. The expression levels of IL-10 and CXCL10 were measured by ELISA and RT-qPCR. The percentage of M2 polarized macrophages was calculated by immunohistochemistry staining using CD163 as M2 surface marker. We also carried out nanostring profiling with IO360 panel to characterize immune cell population in tumor tissue. RESULTS: We found a good correlation between the levels of IL-10 and CXCL10 measured by ELISA in urine samples and the levels determined by RT-qPCR in urine and tumor tissue. In order to define if the presence of M2 macrophages before BCG instillation correlates with the BCG response rate, we quantified CD163-positive cells in tissue samples from responders and non-responders. We found that patients with higher count of CD163+ infiltrating cells show worse response to BCG. We found that IL-10 quantification is a good predictor for BCG response. CONCLUSIONS: The presence of M2 polarized macrophages in TURBT tissue as well as M2 markers in urine samples of bladder cancer patients appear to be predictive for BCG response. However, validation in a larger cohort is needed to confirm our data. Source of Funding: None. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e8-e8 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Felix Guerrero-Ramos* More articles by this author Pablo Abad-Lopez More articles by this author Cristian Suarez-Cabrera More articles by this author Marta Rodriguez-Izquierdo More articles by this author Carmen Gomez-Cañizo More articles by this author Federico de la Rosa-Kehrmann More articles by this author Victor Garcia-Martinez More articles by this author Alejandra Bernardini More articles by this author Iris Lodewijk More articles by this author Guillermo Paramio More articles by this author Alfredo Rodriguez-Antolin More articles by this author Jesus M Paramio More articles by this author Marta Dueñas More articles by this author Expand All Advertisement PDF downloadLoading ...

Garcia

10.1097/ju.0000000000000815.016

Cite

Citations (0)